November 18, 2017 |
Lyme Disease Vaccine Shows Promise in Clinical Trial
May 16, 2013  | 

Results on 300 tested revealed strong immune response to the vaccine

 

Stony Brook, NY – The results of a phase 1/2 clinical trial in Europe of an investigational Lyme disease vaccine co-developed by researchers at Stony Brook University, Brookhaven National Laboratory, and at healthcare company Baxter International S.A., revealed it to be promising and well tolerated, according to a research paper published online in The Lancet Infectious Diseases. The vaccine was shown to produce substantial antibodies against all targeted species of Borrelia, the causative agent of Lyme disease in Europe and the United States. Baxter conducted the clinical trial of the vaccine.

Since the early 1990s, Benjamin Luft, MD, the Edmund D. Pellegrino Professor of Medicine at Stony Brook University School of Medicine, and the late John Dunn, Ph.D., a biologist at Brookhaven National Laboratory, spearheaded the initial development of the original vaccine antigen concept, and together with researchers at Baxter helped bioengineer the formulation used in the clinical trial. 

In the article, “Safety and immunogenicity of a novel multivariant OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomized, dose-escalation phase 1/2 trial,” Principal Investigator P. Noel Barrett, PhD, of Baxter, Biomedical Research Centre, and co-authors evaluated the safety and immunogenicity of the vaccine in a range of doses in 300 people living in Austria and Germany. Study participants received three primary immunizations and one booster immunization. All doses and formulations, some of which included an adjuvant, an additive to stimulate immune response to the vaccine, induced substantial antibody titers against all species of Borrelia. The vaccine demonstrated predominantly mild adverse reactions and no-vaccine related serious events occurred in the sample population. Continue>

Page | 1 2 3
Suggested Articles